- Post-Effective Amendment to an S-8 filing (S-8 POS)
December 21 2012 - 4:08PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on December 21, 2012
Registration No. 333-140771
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT No. 1 to
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CHINA MEDICINE CORPORATION
(Exact name of registrant as specified
in its charter)
Nevada
|
|
|
|
51-0539830
|
(State or other jurisdiction
of incorporation or organization)
|
|
|
|
(I.R.S. employer
identification No.)
|
Guangri Tower, Suite 702
No. 8 Siyou South 1st Street
Yuexiu District
Guangzhou, China 510600
(Address of principal
executive offices) (zip code)
2006 Long-Term Incentive Plan
(Full title of the Plan)
United Corporate Services, Inc.
202 South Minnesota Street
Carson City, Nevada 89703
(800) 899-8648
(Name and address of agent for service)
(800) 899-8648
(Telephone number, including area code,
of agent for service)
Copy to:
Elizabeth Fei Chen, Esq.
Pryor Cashman LLP
7 Times Square
New York, NY 10036-6569
(212) 421-4100
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated
filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
x
|
(Do not check if a smaller reporting company)
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to
the Registration Statement on Form S-8, No. 333-140771, which was originally filed with the Securities and Exchange Commission
(the “SEC”) on February 16, 2007 (the “Registration Statement”), of China Medicine Corporation (the “Company”),
is being filed to terminate the effectiveness of the Registration Statement and remove from registration all securities reserved
for issuance under the Company’s 2006 Long-Term Incentive Plan (the “Plan”) which have not yet been issued under
the Plan as well as securities which have been issued upon the exercise of stock options granted under the Plan but have not yet
been resold. The Registration Statement initially registered a total of 1,575,000 shares of common stock, par value $.0001 per
share (“Common Stock”), of the Company under the Plan.
In the Company’s Current Report on
Form 8-K, which was filed with the SEC on September 27, 2012, the Company announced its intention to deregister its Common Stock
under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). On October 4, 2012, the
Company filed a Form 15 to suspend its reporting obligations under Section 13 of the Exchange Act. The deregistration will become
effective 90 days from the filing of the Form 15. In connection with such actions, the Company terminated the offering contemplated
by the Registration Statement.
In accordance with an undertaking made
by the Company in Part II of the Registration Statement to remove from registration, by means of a post-effective amendment, any
securities which remain unsold at the termination of the offering, the Company hereby amends the Registration Statement to remove
from registration all shares of Common Stock and all other securities registered under the Registration Statement which remain
unsold or otherwise unissued under the Plan.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
this Post-Effective Amendment No. 1 to the Registration Statement and has duly caused this Post-Effective Amendment No. 1 to the
Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Guangzhou in the
People's Republic of China on this 21
st
day of December, 2012.
|
|
CHINA MEDICINE CORPORATION
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Senshan Yang
|
|
|
Senshan Yang
Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
Pursuant to the requirements of the Securities Act of 1933,
this Post-Effective Amendment No. 1 to the Registration Statement was signed by the following persons in the capacities and on
the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Senshan Yang
|
|
Chief Executive Officer
|
|
December 18, 2012
|
Senshan Yang
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Henry Ho
|
|
Chief Financial Officer
|
|
December 18, 2012
|
Henry Ho
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Rachel Gong
|
|
Director
|
|
December 18, 2012
|
Rachel Gong
|
|
|
|
|
|
|
|
|
|
/s/ Ian Robinson
|
|
Director
|
|
December 18 2012
|
Ian Robinson
|
|
|
|
|
|
|
|
|
|
/s/ Ryan Shih
|
|
Director
|
|
December 17, 2012
|
Ryan Shih
|
|
|
|
|
China Medicine (CE) (USOTC:CHME)
Historical Stock Chart
From Dec 2024 to Jan 2025
China Medicine (CE) (USOTC:CHME)
Historical Stock Chart
From Jan 2024 to Jan 2025